Sucampo Pharmaceuticals Down 25% on Arbitration Decision

Loading...
Loading...
Sucampo Pharmaceuticals
SCMP
is trading lower on the session after it announced the final arbitration decision. The International Court of Arbitration, ICC did not agree with Sucampo's claims and did not award any attorney's fees or costs. Also, the decision confirms that the Collaboration Agreement and all of its terms, rights and conditions for AMITIZA® (lubiprostone) will remain in force until it expires in October 2020, including the royalty rate arrangement. Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman and Chief Executive Officer said, “AMITIZA is a brand whose safety and efficacy has been proven over six years and six million patients. Through this arbitration process, we have gained a greater understanding that there is significant potential to further increase AMITIZA's value, make the product available to currently underserved patients, and maximize its net sales revenue by optimizing its marketing and commercialization efforts. We anticipate filing a supplemental new drug application in the near-term for the treatment of opioid-induced constipation which, if approved, would be the third indication for AMITIZA.” Sucampo Pharmaceuticals is currently trading at $5.16, a loss of $1.79 or 25.76%.
Posted In: Intraday UpdateMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...